神經再生：從預測性生物標記到腦部修復

Neuroregeneration: From Predictive Biomarkers to Brain Repair

出版日期: 2026年08月05日 | 出版商:

Frost & Sullivan | 英文 49 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告說明了預測性生物標記如何改變神經發生的格局，將治療理念從抑制腦損傷轉向積極修復腦損傷。報告描述了正在開發的血液檢測方法如何取代基於影像學的腦損傷評估，這些方法可用於測量阿茲海默症的病理負荷、急性腦損傷（例如中風）後的腦損傷情況，以及在多發性硬化症、肌萎縮側索硬化症和失智症多種疾病的首發症狀出現數年前就已存在的早期神經纖維損傷。此外，報告說明了構成腦功能和健康狀況綜合評估方法的各種生物標記，說明如何利用生物標記對患者進行分類、如何把握干預時機以配合修復「時機」，以及如何利用藥效動態物標誌物數據來指示哪些藥物能夠修復大腦以及大腦從損傷中恢復所需的時間。報告中也說明了在人體研究中開發腦修復療法的四種關鍵方法。具體而言，這些療法包括細胞替代療法、中和抑制瘢痕組織形成的化學物質的藥物治療、用於部分逆轉衰老的基因療法，以及用於恢復慢性癱瘓患者站立和行走能力的封閉回路型神經調節療法。該報告還重點闡述了生物標記和療法的各項進展如何與關鍵行業相關人員（包括製藥公司、診斷實驗室、醫療技術開發公司和人工智慧公司）之間不斷變化的競爭格局和創造性合作模式相聯繫。此外，報告還強調了這些進展與新型經營模式將診斷檢測、藥物輸送系統和資訊服務相結合，旨在為神經退化性疾病患者提供全面、以結果為導向的解決方案。

The report describes how predictive biomarkers are changing the global landscape of neuroregeneration and transitioning from the concept of control of brain injury to an active repair of the brain. This report describes how brain injuries from scans were being replaced by blood tests being developed to measure the burden of Alzheimer's disease, measure the presence of brain injury after an acute brain injury (e.g., as a result of a stroke), and measure early nerve fiber damage that will happen for years before the first symptoms of various diseases such as multiple sclerosis, ALS, and dementia occur. Furthermore, this report describes the various types of biomarkers that comprise an integrated approach to the measurement of brain function and health, describes how biomarkers are being used to categorize patients, time interventions to windows of opportunity for repair, and use pharmacodynamic biomarker data as an indication of what drugs will repair the brain, and serve as an indication of how long the brain will take to recover from injuries. The report describes four major methods used in human studies to develop brain repair therapies in cell replacement; pharmacologic treatments that neutralize chemicals that inhibit the formation of scar tissue; partial resetting of aging through gene therapy; and closed loop neuromodulation to restore standing and stepping ability to subjects with chronic paralysis. The report also highlights the linkage of various advances in biomarkers and therapies to changes in competition and creative partnerships among key participants in the industry, including pharmaceutical companies, diagnostic laboratories, medtech developers, and artificial intelligence firms; and to new business models that will combine diagnostic tests, therapeutic delivery systems and the delivery of data services to create complete outcomes based solutions for patients with neurodegenerative disorders.

Strategic Evolution of Biomarker Technologies

Global Burden of Brain Disease and Injury
Limits of Spontaneous Regeneration of Brains and Neurons
From Neuroprotection and Neurorestoration to Neuroregeneration
Biomarkers and Brain-Repair Strategies
Biochemical Biomarkers
Molecular Biomarkers
Imaging Biomarkers

Key Companies Driving Innovation Across Brain Disease and Neurorepair Biomarkers

Leading Innovators in Biomarkers for Brain Disease and Repair

Funding, Partnerships, & Acquisitions

Funding Architecture
Brain Repair: Investment
Strategic Partnerships & Initiatives Advancing Brain Repair

Outlook - Future Directions and Prospects

Biochemical Biomarkers: Fluid-Based Dynamics & Re-Engineering
Molecular Biomarkers: Genetic Reprogramming & Transcriptomic
Imaging Biomarkers: Macroscopic Brain Topology & Synaptic Reconnection

Growth Opportunity Universe

Growth Opportunity 1: Liquid Biopsy Multi-Omics for Real-Time Treatment Calibration
Growth Opportunity 2: Directed In Vivo Glial Reprogramming via Programmed Nucleic Acid Vectors
Growth Opportunity 3: Digital Twin Connectomics and Synaptic Radiotracers for Circuit Verification